Advanced search
Publication Cover
Journal of Chemotherapy Volume 35, 2023 - Issue 8
Submit an article Journal homepage
700
Views
0
CrossRef citations to date
0
Altmetric
Anticancer Original Research Paper

Clinical outcome and safety profile of metastatic pancreatic cancer patients treated with more than six cycles of nab-paclitaxel plus gemcitabine

Alberto D’Angeloa Department of Life Sciences, University of Bath, Bath, UK;b Department of Oncology, Royal United Hospital, Bath, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-8417-9172
ORCID Icon,
Martina Catalanoc School of Human Health Sciences, University of Florence, Florence, Italy
,
Raffaele Concad Division of Medical Oncology, Department of Onco-Hematology, IRCCS-CROB, Referral Cancer Center of Basilicata, Vulture, Potenza, Italy;e Department of Oncology, San Bortolo General Hospital, Vicenza, Italy
,
Roberto Petriolif Department of Medicine, Surgery and Neurosciences, Medical Oncology Unit, University of Siena, Siena, Italy
,
Francesca Siminonatoe Department of Oncology, San Bortolo General Hospital, Vicenza, Italy
,
Alessandro Cappettae Department of Oncology, San Bortolo General Hospital, Vicenza, Italy
,
Giandomenico Roviellog Department of Health Sciences, University of Florence, Florence, Italy
&
Monica Ramelloh Oncology Unit, Department of Medical, Surgical, & Health Sciences, University of Trieste, Trieste, Italy
 show all
Pages 753-759 | Received 13 Jun 2022, Accepted 09 Mar 2023, Published online: 11 May 2023

References

  • Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249; [cited 2022 Apr 11]. Available from https://pubmed.ncbi.nlm.nih.gov/33538338/
  • Haeberle L, Esposito I. Pathology of pancreatic cancer. Pathology of pancreatic cancer. Transl Gastroenterol Hepatol. 2019;4:50.
  • Treatment for potentially resectable exocrine pancreatic cancer. Last accessed Feb 2023 . https://www.uptodate.com/contents/treatment-for-potentially-resectable-exocrine-pancreatic-cancer
  • Bilimoria KY, Bentrem DJ, Ko CY, et al. Validation of the 6th edition AJCC pancreatic cancer staging system: report from the national cancer database. Cancer. 2007;110(4):738–744.
  • Conroy T, Desseigne F, Ychou M, PRODIGE Intergroup, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–1825.
  • Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-Paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–1703.
  • Catalano M, Roviello G, Conca R, et al. Clinical outcomes and safety of patients treated with NAb-Paclitaxel Plus gemcitabine in metastatic pancreatic cancer: the NAPA study. Curr Cancer Drug Targets. 2020;20(11):887–895.
  • Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247.
  • Blomstrand H, Scheibling U, Bratthäll C, et al. Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer. BMC Cancer. 2019;19(1):40.
  • Wang Y, Camateros P, Cheung WY. A Real-World comparison of FOLFIRINOX, gemcitabine Plus nab-Paclitaxel, and gemcitabine in advanced pancreatic cancers. J Gastrointest Canc. 2019;50(1):62–68.
  • Kobayashi S, Ueno M, Ikeda M, et al. A multicenter retrospective study of gemcitabine Plus Nab-Paclitaxel for elderly patients with advanced pancreatic cancer. Pancreas. 2020;49(2):187–192.
  • Montes AF, Villarroel PG, Ayerbes M, et al. Prognostic and predictive markers of response to treatment in patients with locally advanced unresectable and metastatic pancreatic adenocarcinoma treated with gemcitabine/nab-paclitaxel: results of a retrospective analysis. J Cancer Res Ther. 2017;13(2):240–245.
  • Papneja N, Zaidi A, Chalchal H, et al. Comparisons of outcomes of real-world patients with advanced pancreatic cancer treated with FOLFIRINOX versus gemcitabine and nab-paclitaxel: a population-based cohort study. Pancreas. 2019;48(7):920–926.
  • Lo Re G, Santeufemia DA, Foltran L, et al. Prognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: a single institutional experience. Oncotarget. 2015;6(10):8255–8260.
  • De Vita F, Ventriglia J, Febbraro A, et al. NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice. BMC Cancer. 2016;16(1):709.
  • Fukahori M, Miwa K, Murotani K, et al. A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer. Medicine (Baltimore). 2021;100(20):e26052.
  • Philip PA, Lacy J, Portales F, et al. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Lancet Gastroenterol Hepatol. 2020;5(3):285–294.
  • Kokkali S. Biweekly gemcitabine/Nab-Paclitaxel as first-line treatment for advanced pancreatic cancer. In Vivo (Brooklyn). 2018;32(3):653–657.
  • Macarulla T, Pazo-Cid R, Guillén-Ponce C, et al. Phase I/II trial to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with pancreatic cancer and an ECOG performance status of 2. J Clin Oncol. 2019;37(3):230–238.
  • Corrie PG, Qian W, Basu B, et al. Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. Br J Cancer. 2020;122(12):1760–1768.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.